For those new: COVID-19 prophylactic/therapeutic...and tilmanocept -"CD206.... co-register with inf | NAVB Message Board Posts


Navidea Biopharmaceuticals, Inc.

  NAVB website

NAVB   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  37689 of 37791  at  8/5/2022 10:57:29 PM  by

moneyonomics

The following message was updated on 8/5/2022 10:59:24 PM.

 In response to msg 36717 by  ddin
view thread

Re: For those new: COVID-19 prophylactic/therapeutic...and tilmanocept -"CD206.... co-register with infectious SARS-CoV-2...The likelihood that macrophages are the instigator of the cytokine storm in liver as well as lung, is high."

 
Should be seeing Granted Patent Published soon..hopefully Navidea added
 
  The following message was updated on 3/26/2022 6:50:48 PM.
Msg  36717 of 37689  at  3/26/2022 6:49:05 PM  by

ddin

 report abuse




COVID-19 prophylactic/therapeutic, Dr. Cope and tilmanocept - tying it all together


As many who have been here a while, Dr. Cope left Navidea and started Physis International a few years ago.

https://physisinternational.com/

Back in October, Money discussed one of the agents they were developing, called PI-OC-T/G-0001PF

https://www.investorvillage.com/smbd.asp?mb=8699&mn=35170&pt=msg&mid=22506769

Another agent they were developing was a therapeutic for COVID, CT-RX-I/I-001TL

(9 October 2020) Physis received a follow-up data assessment regarding the potential therapeutic efficacy of Covid-19 therapeutic agent CT-RX-I/I-0001TL: Physis has received a second prospective data set evaluating the potential of its anti-Covid-19 agent in Covid-19-infected human tissues derived from deceased infected patients. The data further indicate that 0001TL has a strong potential to provide significant relief from Covid-19 -induced symptoms even in later stages of the infection. The data, again, suggest that cell types other than those expressing ACE2-r may be involved in infection and/or disease progression. Physis is completing a third round of evaluations in a large patient population tissue sample.

(15 December 2020 & 12 January 2021) Physis receives positive test results affecting the potential development of its Covid-19 therapeutic agent CT-RX-I/I-001TL. Physis has received data evaluations from human tissue samples from Covid-19+ that further suggest that its agent would provide significant benefit to SARs-Cov-2-infection. These data cover pulmonary, liver and GI assessments. Physis is pursuing the IP and development of this product set.

(01 January 2022 /01 July 2021) Physis receives USPTO review of Covid-19 therapeutic agent CT-RX-I/I-0001TL - Physis submits final IP package to USPTO for an anti-Covid agent. Physis submits final patent documents (CT-RX-I/I-001TL) to the USPTO for use in treating Covid 19 disease. This patent is based on Physis' data derived from cadaver tissue assessments. Physis has received a review from the USPTO and is completing its reply for final claims for the product. Physis presented these data at the annual AAPS forum in Philadelphia on 19 October 2021 in an open forum for AAPS attendees. Physis received a positive review of these data.

I finally found the AAPS abstract, and the therapeutic is surprisingly enough uses tilmanocept as a prophylactic and therapeutic to fight against the cytokine storm in the lungs that results from COVID-19.

(W7110V) Pulmonary Macrophages as a Prophylactic/Therapeutic Target for Covid 19: Striking at the CD206 Receptor

Conclusion: 1.CD206, CD163 and CD11b all co-register with infectious SARS-CoV-2; 2. Substantially fewer viral elements are present in the alveolar endothelial cells; 3. Macrophages are the overwhelming cytotype in the deep lung that are targeted by the late stage CV19 disease; 4. The likelihood that macrophages are the instigator of the cytokine storm and Covid progression is high; 5. Modulation of these macrophages in Phases 2-4 (DAMP) with the absence of DISP factors may truly establish a TARGETED therapeutic rescue by modulation of these macrophage states; 6. The use of the targeted approach with tilmanocept may eliminate a virus tolerization and replication state, resulting in the elimination of the massive trans-alveolar migration/recruitment of monocytes that drive a populating process which adds significantly to the alveolar macrophage population, further exacerbating the clinical symptomology and driving the patient to a DISP clinical state; 7. The likelihood that macrophages are the instigator of the cytokine storm in liver as well as lung, is high.

https://www.eventscribe.net/2021/PharmSci360/fsPopup.asp?efp=RUFBQ05LUEUxMzM0OA&PosterID=427719&rnd=0.0145818&mode=posterinfo

Sounds like Cope et. al. are developing an additional patent for treatment of Covid based on the Compounds and Methods for Diagnosis and Treatment of Viral Infections patent he developed while at Navidea. Good to hear of another therapeutic based on tilmanocept being developed that has been publicly presented along with the cancer therapeutic that Navidea is developing.

Original Message (# 36717) by ddin on 3/26/2022 6:49:05 PM

Collapse Original Message


 
 
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 2  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...